# OnCo record left-ventricular-dysfunction-on-her2-targeted-drugs (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/left-ventricular-dysfunction-on-her2-targeted-drugs/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "left-ventricular-dysfunction-on-her2-targeted-drugs" ;
  schema:name "Fall in heart pumping function (ejection fraction) on HER2-targeted drugs: scans and the hold, restart and stop rules by product"@en ;
  schema:alternateName "LVEF decline on trastuzumab"@en, "trastuzumab cardiotoxicity hold rules"@en, "left ventricular dysfunction on pertuzumab"@en, "ejection fraction fall on trastuzumab emtansine"@en, "ejection fraction fall on trastuzumab deruxtecan"@en, "HER2 therapy cardiac dysfunction"@en, "when to stop trastuzumab for the heart"@en ;
  schema:description "Trastuzumab and other HER2-targeted drugs can weaken the heart's pumping, so your team scans your heart before and during treatment. If the pumping measure (ejection fraction) falls past a set line, the drug is usually paused, the scan repeated in 3 to 4 weeks, and treatment restarted if it recovers. The lines differ by drug and country. Report new breathlessness or ankle swelling straight away."@en ;
  schema:url <https://onco.cc/protocols/left-ventricular-dysfunction-on-her2-targeted-drugs/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:tag "protocol", "cardio-oncology", "her2" ;
  onco:related <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/cardiomyopathy-surveillance-after-childhood-cancer/>, <https://onco.cc/protocols/irae-myocarditis/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/margetuximab/>, <https://onco.cc/drugs/lapatinib/> ;
  onco:institutions <https://onco.cc/institutions/esmo/>, <https://onco.cc/institutions/ema/> ;
  onco:terms <https://onco.cc/terms/trastuzumab-cardiotoxicity/>, <https://onco.cc/terms/cardiotoxicity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lyon-eur-heart-j/> .
